Customer Center
Login | Register

Investor Relations

  • Banner Image

News Release

  View printer-friendly version
<< Back
Luminex Technology Selected by Assurex Health
xTAG® Technology to Aid in GeneSight® Precision Medicine Test

AUSTIN, Texas, March, 12, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that its xTAG® Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health's patented GeneSight® tests. 

Healthcare providers use GeneSight to help patients affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, ADHD, and acute and chronic pain. 

This agreement incorporates Luminex's open-architecture xTAG Technology into the GeneSight testing process and enables large numbers of tests to be conducted and analyzed quickly, cost-effectively, and accurately.

"With our unique portfolio of pharmacogenetics assays, flexible platforms, and support, Luminex is delighted to be selected as the partner of choice by Assurex Health," said Homi Shamir, President and CEO of Luminex. "Assurex Health is at the forefront of the fast-growing field of personalized medicine, and we are excited that our technology will be a part of this solution. We look forward to partnering with Assurex Health in their goal of helping clinicians determine the right therapeutics for their patients."

"Luminex's highly sensitive xTAG Technology will improve our workflow efficiency without increasing cost," said Donald R. Wright, Executive Vice President and Chief Operating Officer, Assurex Health. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand."

Pharmacogenetics Innovation at Luminex
Luminex launched its first test to aid in personalized medicine in 2010. Since that time, Luminex has received Health Canada Approval, U.S. FDA clearance, and European clearance for its xTAG CYP2D6 Kit v3 and xTAG CYP2C19 Kit v3 assays. Luminex is a member of the Personalized Medicine Coalition.

For more information on Luminex's pharmacogenetic assays, visit: www.luminexcorp.com/CYP2D6 or www.luminexcorp.com/CYP2C19.

Learn more about the Personalized Medicine Coalition: http://www.personalizedmedicinecoalition.org/

About Luminex Corporation
Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research, and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.

About Assurex Health
Assurex Health is a commercial-stage, informatics-based, precision medicine company providing treatment decision support to clinicians for behavioral health conditions. Assurex Health's proprietary GeneSight technology is based on combinatorial pharmacogenomics (CPGxTM) – the study of the genetic factors that influence an individual's response to medications, including evidence-based medicine and clinical pharmacology.  Assurex Health has licensed patented technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center, both of whom continue to be research collaborators.  Learn more at www.assurexhealth.com  

Contacts
Luminex Investor Contact
Harriss Currie
Sr. Vice President of Finance and CFO
512.219.8020
[email protected]

Luminex Media Contact
Christine Valle
Sr. Manager, Global Marketing
512.219.8020
[email protected]

Disclaimer: The financial terms of the multi-year agreement were not disclosed.

Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/luminex-technology-selected-by-assurex-health-300049711.html

SOURCE Luminex Corporation